New therapy for blood cancers using drug combo

Clinical researchers have successfully completed a Phase I clinical trial evaluating a combination of the drugs bortezomib and alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

Read the whole article on Science Daily

More from Science Daily